We're making updates and relaunching soon. Get notified

Straight answers about GLP-1 medications

Plain-language guides on dosing, side effects, costs, and what to look for in a provider.

Relaunching Soon

  • Relaunching as an independent GLP-1 guide
  • Get notified when we relaunch
  • We only ask for your email
Get Started

One email to confirm. Unsubscribe anytime.

GLP-1 Weight Loss Without Insurance: Costs & Options

This content is for general education and is not medical advice. Transformation Health is an independent GLP-1 guide. It does not prescribe, sell, or ship medication, and it has no prices of its own. Compounded medications are not FDA-approved and are not the same as brand-name products such as Wegovy or Zepbound. Transformation Health does not accept payment from providers. How we make money.

You called your insurance company. Or you checked the benefits portal. Either way, the answer was no. GLP-1 medications for weight management are not covered under your plan.

That is frustrating, and it is also a common place to start. Insurance coverage for weight management is limited, and many people who use GLP-1 medications for weight loss pay out of pocket. That is why cash-pay telehealth programs and manufacturer self-pay options exist, and why it pays to know exactly what a price covers.

This page covers what you need to know: why insurance rarely covers this, the main routes people use without coverage, what to compare, and what the FDA labels say about who these medications are for.

Why insurance almost never covers GLP-1 for weight management

If you were denied coverage, it is worth understanding why, because it affects how you approach this.

Many commercial insurance plans cover GLP-1 receptor agonists for type 2 diabetes but not for weight management. When those same medications are used for weight management in people without diabetes, coverage is often denied. Coverage policy and clinical evidence do not always move together.

Here is what typically happens:

Many formularies separate GLP-1 medications by indication. Your insurer may cover a semaglutide product approved for diabetes but exclude the semaglutide product approved for weight management. These are treated as separate coverage categories, even though both contain semaglutide.

Prior authorization requirements are strict. Plans that do cover obesity medications often require documented prior attempts at weight loss, specific BMI thresholds, documentation of weight-related conditions, and sometimes appeals. Some people who meet the clinical criteria still do not get past the administrative process. See GLP-1 prior authorization for how it works.

Some plans exclude obesity medications entirely. Employer-sponsored plans have wide latitude in their benefit design, and some exclude anti-obesity medications from their formularies altogether.

The Medicare Part D benefit generally does not cover GLP-1 medications for weight management alone. Federal law lets Part D exclude “agents when used for anorexia, weight loss, or weight gain,” and bills to change that had not become law as of 2026-10-16[1]. Part D plans may cover a GLP-1 for another FDA-approved use, such as type 2 diabetes. Separately, CMS is running a short-term demonstration, the Medicare GLP-1 Bridge, that gives eligible Part D beneficiaries access to certain GLP-1 drugs from July 1, 2026 through December 31, 2027[2]. Eligibility and covered products are set by CMS, so check the CMS page or call 1-800-MEDICARE. Medicaid coverage varies by state.

The short version: if you do not have type 2 diabetes, your odds of getting insurance coverage for GLP-1 treatment are low with many plans. Ask your plan directly, then look at the routes below.

Cash-pay telehealth as the actual path forward

For many people without coverage, a cash-pay telehealth program is the most direct route, and it is not the only one. Manufacturer self-pay options, patient assistance programs, and older generic medications are also worth comparing.

The cash-pay model removes some barriers that make insurance-based care frustrating. There is no prior authorization process and no waiting on an insurer. What you trade for that is the full cost, so pricing transparency matters. Programs package the pieces differently: some bundle the medication, provider visits, labs, and shipping into one monthly fee, and others bill each piece separately.

What matters in a cash-pay program is that it tells you, in writing and before you pay, what one payment covers and what it will cost at each dose. The next section walks through the routes and what to check for each.

Program options to review

Prices vary by program and dose. For each route, compare the total cost: medication, dose increases, provider visits, labs, shipping, membership fees, and cancellation terms.

RouteWhat it isFDA status of the medicationWhat to check
Manufacturer self-payBuying a brand-name product directly at the manufacturer’s self-pay price, with a prescription from a provider you chooseFDA-approvedPrice at each dose, which doses are offered, whether any introductory price ends, and the separate cost of the provider visits
Cash-pay telehealth (brand-name)A telehealth program prescribes a brand-name product; care is billed by the program and medication by the pharmacy or manufacturerFDA-approvedMembership or visit fees, what the medication costs at each dose, and cancellation terms
Cash-pay telehealth (compounded)A telehealth program prescribes compounded semaglutide or tirzepatide prepared by a compounding pharmacyNot FDA-approvedPharmacy name and license, what the price includes at each dose, and cancellation terms
Patient assistance programsManufacturer or charity programs for people who meet income and insurance criteriaDepends on the programIncome and insurance requirements, which products are covered, and how to apply
Older generic medicationsOlder FDA-approved weight-loss medications, some sold as generics at retail pharmaciesFDA-approvedCash price at local pharmacies, label warnings, and whether a provider decides one is appropriate

Transformation Health does not accept payment from providers. How we make money.

Manufacturer self-pay

Both manufacturers sell some brand-name products directly to people paying cash. Wegovy self-pay prescriptions are filled through NovoCare Pharmacy, and Zepbound self-pay is available through LillyDirect Pharmacy or other pharmacies[3][4]. As of 2026-10-16, both manufacturers’ self-pay prices vary by dose, and Novo Nordisk lists an introductory price for the first two monthly fills at the starting doses for new patients, through December 31, 2026[3]. Lilly’s page says self-pay costs cannot be submitted to insurance or applied to a deductible[4]. You still need a prescription from a licensed provider, and that care is billed separately. Manufacturer savings cards are a different thing: they are generally for people with commercial insurance and exclude government coverage. See GLP-1 savings programs for current terms and how to check them.

Cash-pay telehealth: brand-name or compounded

Some cash-pay telehealth programs prescribe brand-name products, and some prescribe compounded semaglutide or tirzepatide. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality before they are marketed[5]. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound and may differ in formulation, purity, and potency.

The FDA determined that the tirzepatide injection shortage was resolved on December 19, 2024, and that the semaglutide injection shortage was resolved on February 21, 2025. Its enforcement discretion periods for shortage-based compounding ended in 2025, and the conditions under which pharmacies may compound these drugs are now much narrower (FDA page content current as of 04/01/2026)[6]. Availability and pricing of compounded products can change.

If you are considering a compounded product, ask which pharmacy prepares it, whether it is a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility, and check its license with your state board of pharmacy. Our compounding pharmacy checklist walks through what to look up, and the cash-pay telehealth cost guide covers the pricing models in detail.

What “all-inclusive” can mean

This is worth being specific about, because the pricing model matters. “All-inclusive” is a program’s own label, not a standard, and it means different things at different programs. Before you pay, ask whether the monthly price covers:

  • The medication, at which doses, and whether the price changes as the dose goes up. For compounded products, which pharmacy prepares it and ships it
  • Provider care, including the first review, refill or dose-change reviews, and follow-up
  • Lab work, which labs are required, how often, where they are drawn, and whether the cost is included or billed separately
  • Messaging or support, and how you reach someone with side effect questions
  • Supplies and shipping, on every order and at every dose

Also ask about prepay requirements, auto-renewal, and how to cancel. If a program will not tell you clearly what is included, assume something is billed separately and ask.

Patient assistance programs and older generic medications

Patient assistance programs are separate from savings cards and self-pay prices. They can have income and insurance requirements, and they cover specific products. NeedyMeds keeps a searchable database of them[7]. Our patient assistance guide covers how to look for one.

Older generic medications are another route people compare. Before semaglutide and tirzepatide, the FDA approved several other weight-loss medications, and some are now sold as FDA-approved generics. As of 2026-10-16, Drugs@FDA lists approved generic versions of liraglutide 3 mg (Saxenda), the first approved on August 27, 2025, and of phentermine and topiramate extended-release (Qsymia); phentermine is sold widely as a generic; naltrexone and bupropion extended-release (Contrave) and orlistat had no generic on the market[8]. These are not interchangeable with semaglutide or tirzepatide, and each has its own label warnings: liraglutide carries a boxed warning about thyroid C-cell tumors[9], phentermine and topiramate can cause birth defects and is a Schedule IV controlled substance[10], and phentermine alone is approved only for short-term use[11]. A licensed provider decides whether any of them is appropriate. For label trial results, safety information, and generic status for each, see cheaper alternatives to brand-name GLP-1 medications.

FSA and HSA: using pre-tax dollars

Whether a Flexible Spending Account (FSA) or Health Savings Account (HSA) can pay for a GLP-1 prescription is a tax and plan question. Check with your plan administrator or a tax professional before you pay, especially if a program’s monthly fee bundles medication with other services. Whether a program accepts HSA or FSA cards is up to that program. For what the IRS says and how to check your plan, see using an FSA or HSA for GLP-1 medication.

Who qualifies: eligibility requirements

There is no single number, because a licensed provider decides case by case. What the FDA labels do define is who the medications are approved for. For weight management, Wegovy is indicated for adults with obesity (the injection also for children 12 and older with obesity), and adults with overweight and at least one weight-related condition[12]. Zepbound is indicated for adults with obesity, or adults with overweight and at least one weight-related condition[13]. Both are used with a reduced-calorie diet and increased physical activity.

NIDDK describes the adult thresholds for weight management medications as[14]:

  • A BMI of 30 or higher, or
  • A BMI of 27 or higher with weight-related health problems, such as high blood pressure or type 2 diabetes

What the provider is evaluating:

A provider looks at your full clinical picture, not just your BMI. This includes your current medications (to check for interactions), your medical history, and conditions that rule a medication out. Meeting a BMI threshold does not mean a prescription is appropriate.

Safety information from the labels:

The Wegovy and Zepbound labels both carry a boxed warning about the risk of thyroid C-cell tumors, and both say the medication should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, or with a known serious hypersensitivity to the drug. The labels also list warnings for acute pancreatitis, gallbladder disease, low blood sugar (especially with insulin or sulfonylureas), kidney injury from dehydration, and severe gastrointestinal reactions. The most common side effects are gastrointestinal, including nausea, diarrhea, vomiting, constipation, and abdominal pain[12][13].

If a prescription is not written:

Programs handle this differently. Some do not charge until a licensed provider decides a prescription is appropriate, some charge a visit fee either way, and some refund it. Ask which applies before you start.

Where you live:

Ask whether the provider is licensed in your state, whether your state requires a live video visit, and whether that visit costs extra.

What is in this section

These pages cover specific topics related to accessing GLP-1 treatment without insurance:

Obesity Prevalence by State – State-level data on obesity rates and the gap between how common obesity is and how many people get treatment.

Cash-Pay Telehealth: What It Actually Costs – How telehealth pricing models work, what different programs include and exclude, and how to work out the total cost.

GLP-1 Patient Assistance and Manufacturer Savings – How patient assistance programs, manufacturer savings cards, and self-pay options work, and who each one is for.

How to Qualify for GLP-1 Without Insurance – What the FDA labels say about who these medications are for, what a licensed provider reviews, and what records to have ready.


For an overview of the routes to a prescription, see the Get Prescription guide. A licensed provider decides whether a prescription is appropriate.

Transformation Health does not accept payment from providers. How we make money.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

Citations

[1] 42 U.S.C. 1395w-102(e)(2)(A) (definition of covered Part D drug; exclusions, incorporating the 42 U.S.C. 1396r-8(d)(2) list, including “agents when used for anorexia, weight loss, or weight gain”). https://www.law.cornell.edu/uscode/text/42/1395w-102

[2] Centers for Medicare and Medicaid Services. “Medicare GLP-1 Bridge.” Accessed 2026-10-16. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge (Supports: short-term demonstration for eligible Part D beneficiaries, July 1, 2026 through December 31, 2027, operating outside the Part D benefit.)

[3] Novo Nordisk. “Save on Wegovy” (coverage and savings). https://www.wegovy.com/coverage-and-savings/save-on-wegovy.html (Accessed 2026-10-16. Supports: cash prescriptions filled through NovoCare Pharmacy; self-pay pricing varies by dose; introductory offer for two monthly fills at the starting doses through December 31, 2026.)

[4] Eli Lilly and Company. “Zepbound Coverage and Savings.” https://zepbound.lilly.com/coverage-savings (Accessed 2026-10-16. Supports: self-pay through LillyDirect Pharmacy or another pharmacy; self-pay price varies by dose; self-pay costs cannot be submitted to insurance or applied to a deductible.)

[5] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Content current as of 09/16/2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (Accessed 2026-10-16. Supports: compounded drugs are not FDA-approved; FDA does not verify their safety, effectiveness, or quality.)

[6] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16. Supports: tirzepatide shortage resolved 12/19/2024; semaglutide shortage resolved 2/21/2025; end of enforcement discretion periods.)

[7] NeedyMeds. “Patient Assistance Programs Database.” Accessed 2026-10-16. https://www.needymeds.org/

[8] U.S. Food and Drug Administration. Drugs@FDA application records, via the openFDA Drugs@FDA API (https://api.fda.gov/drug/drugsfda.json), checked 2026-10-16: liraglutide (NDA 206321 Saxenda; ANDA 214568 approved 08/27/2025, with later ANDAs approved 02/24/2026); phentermine and topiramate (NDA 022580 Qsymia; ANDAs 204982 and 208175 approved); naltrexone and bupropion (NDA 200063 Contrave; ANDA 208043 tentative approval only); orlistat (NDA 020766 Xenical; NDA 021887 Alli; no ANDA listed); phentermine (ANDA 085128 Adipex-P and other generic phentermine applications).

[9] U.S. Food and Drug Administration. SAXENDA (liraglutide) injection, prescribing information. Revised 02/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321Orig1s024lbl.pdf (Supports: boxed warning.)

[10] U.S. Food and Drug Administration. QSYMIA (phentermine and topiramate extended-release capsules), prescribing information. Revised 03/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022580s032lbl.pdf (Supports: Schedule IV status; birth defect risk and contraindication in pregnancy.)

[11] U.S. Food and Drug Administration. ADIPEX-P (phentermine hydrochloride) tablets and capsules, prescribing information. Rev. 1/2012 (the most recent label posted on Drugs@FDA as of 2026-10-16). https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf (Supports: short-term indication.)

[12] U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf (Supports: indications including pediatric patients 12 and older for the injection; boxed warning; contraindications; warnings; most common adverse reactions.)

[13] U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection, prescribing information. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf (Supports: indications; boxed warning; contraindications; warnings; most common adverse reactions.)

[14] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Prescription Medications to Treat Overweight & Obesity.” https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity (Accessed 2026-10-16. Supports: adult BMI thresholds.)

[15] Aronne LJ, Sattar N, Horn DB, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA. 2024;331(1):38-48. PMID 38078870. https://pubmed.ncbi.nlm.nih.gov/38078870/ (Supports: FAQ statement on weight regain after switching to placebo and continued loss with continued treatment.)

Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, ship, or sell medication, and it has no prices, plans, or programs of its own. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound and may differ in formulation, purity, and potency. Trial and label information on this page applies to the FDA-approved products studied. Results vary. Trial results describe study participants and are not a prediction for any individual. Manufacturer self-pay terms described on this page were observed on each manufacturer's website on 2026-10-16 and may have changed; confirm current prices and terms with the manufacturer or provider. Wegovy and Saxenda are trademarks of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Qsymia, Contrave, Xenical, Alli, and Adipex-P are trademarks of their respective owners. Transformation Health is not affiliated with or endorsed by any of these companies. Transformation Health does not accept payment from providers. How we make money.

FAQ

Frequently Asked Questions

Everything you need to know about getting started.

Still have questions?

Contact our support team
My insurance denied GLP-1 coverage. Is that normal?
It is common. Many commercial plans cover GLP-1 medications for type 2 diabetes but not for weight management alone, and plans that do cover weight management often require prior authorization with criteria that can be hard to meet. Federal law also lets Medicare Part D and state Medicaid programs exclude drugs used for weight loss. You are not an outlier. Ask your plan for the written reason for the denial, and see the guide to GLP-1 prior authorization for what an appeal can and cannot do.
What does an "all-inclusive" price usually cover?
It depends on the program. "All-inclusive" is a marketing label, not a standard. One program's bundle may include provider visits, labs, supplies, shipping, and every dose; another's may cover only the starting dose and bill labs separately. Ask each program, in writing, which doses the price covers, whether visits, labs, supplies, and shipping are included, and what the cancellation terms are.
Can I use my FSA or HSA card?
It depends on IRS rules and your plan, so treat it as a tax and plan question. Check with your plan administrator or a tax professional before you pay, and see the guide to using an FSA or HSA for GLP-1 medication. Whether a program accepts HSA or FSA cards is up to that program.
What if I do not meet the BMI threshold?
A licensed provider decides whether a prescription is appropriate. For weight management in adults, the Wegovy and Zepbound labels cover adults with obesity, or adults with overweight and at least one weight-related condition. NIDDK describes this as a BMI of 30 or greater, or 27 or greater with weight-related health problems such as high blood pressure or type 2 diabetes. If those do not fit you, ask a provider what options make sense for your situation.
Are telehealth programs available in my state?
It depends on the program. Some states have rules about how a telehealth visit must be conducted, which can mean a live video visit instead of an online questionnaire. Ask each program whether its provider is licensed in your state, whether your state requires a live visit, and whether that visit costs extra.
Will I need to keep paying once I reach my goal?
Possibly, and it is worth planning for. In the SURMOUNT-4 trial of tirzepatide (Zepbound), participants who were switched to placebo after 36 weeks regained a substantial share of the weight they had lost, while those who stayed on tirzepatide, on average, continued to lose weight. Whether and how to change or stop a medication is a decision for you and a licensed provider. When you compare costs, look at the price at the dose you are likely to stay on, not only the starting dose.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

About This Site: Disclosures

Who We Are

transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. Providers and programs mentioned on this site are independent third parties.

How We Make Money

Transformation Health does not accept payment from providers.

Educational Purpose

This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Results vary. Trial results describe study participants and are not a prediction for any individual.

Compounded Medications

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy, Ozempic, Zepbound, or Mounjaro. They may differ in formulation, purity, and potency.

Trademarks

Wegovy and Ozempic are trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.